AC
ESPR

Aisling Capital’s Esperion Therapeutics ESPR Stock Holding History

Aisling Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-837,125
Closed -$42M – 13
2017
Q3 		$42M Hold
837,125
– – 6.89% 4
2017
Q2 		$38.7M Hold
837,125
– – 6.64% 4
2017
Q1 		$29.6M Sell
837,125
-800,000
-49% -$18.3M 5.38% 6
2016
Q4 		$20.5M Hold
1,637,125
– – 4.77% 6
2016
Q3 		$22.7M Hold
1,637,125
– – 4.67% 9
2016
Q2 		$16.2M Hold
1,637,125
– – 3.82% 12
2016
Q1 		$27.7M Hold
1,637,125
– – 5.54% 8
2015
Q4 		$36.4M Hold
1,637,125
– – 6.28% 5
2015
Q3 		$38.6M Hold
1,637,125
– – 6.79% 5
2015
Q2 		$134M Sell
1,637,125
-417,469
-20% -$40.9M 19.93% 1
2015
Q1 		$190M Hold
2,054,594
– – 24.9% 1
2014
Q4 		$83.1M Hold
2,054,594
– – 12.6% 1
2014
Q3 		$50.3M Hold
2,054,594
– – 9.75% 2
2014
Q2 		$32.5M Buy
+2,054,594
New +$29.7M 9.41% 7

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aisling Capital's ESPR Position: Q4 2017 in Review

Aisling Capital sold out of Esperion Therapeutics (ESPR) in Q4 2017, closing a stake of 837,125 shares — an estimated $42M sold.

Aisling Capital first reported a position in ESPR in Q2 2014 and held it in 14 quarters. The position peaked at $190M in Q1 2015. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2017.

  • Aisling Capital reported no remaining Esperion Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Aisling Capital sold 837,125 Esperion Therapeutics shares in Q4 2017, an estimated $42M.
  • Aisling Capital first reported a position in Esperion Therapeutics in Q2 2014 and held it in 14 quarters.
  • Aisling Capital's Esperion Therapeutics position peaked at $190M in Q1 2015.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2017.

Based on Aisling Capital's 13F filing for Q4 2017, filed 7 Feb 2018.